|
|
|
|
The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?
_ The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?.
|
|
|
Research and Markets: Pain Therapeutics - Drugs, Markets and Companies
Research and Markets (http://www.researchandmarkets.com/research/269a67/pain_therapeutics) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.This report describes the latest...
|
|
|
The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?
_ The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?.
|
|
|
Updates for Alkermes (NASDAQ:ALKS), Allergan (NYSE:AGN), Aradigm (OTC:ARDM)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL DosePro
- Aradigm Corporation (OTCBB:ARDM) (the Company) announced today that it received the $4 million milestone payment from Zogenix, Inc.(Zogenix) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free...
|
|
|
Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment
Aradigm Corporation (OTCBB:ARDM) (the Company) announced today that it received the $4 million milestone payment from Zogenix, Inc.(Zogenix) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free...
|
|
|
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Aradigm Corporation (OTCBB:ARDM) (the Company) announced today that it received the $4 million milestone payment from Zogenix, Inc.(Zogenix) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free...
|
|
|
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB: ARDM.OB) (the ?Company?) announced today that it received the $4 million milestone payment from Zogenix, Inc.(?Zogenix?) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (...
|
|
|
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
HAYWARD, Calif.-- (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the Company) announced today that it received the $4 million milestone payment from Zogenix, Inc.(Zogenix) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (...
|
|
|
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL DosePro
HAYWARD, Calif.The receipt of this milestone reflects our strategy to raise non-dilutive capital by monetizing non-strategic assets, said Dr. Igor Gonda, the Company's CEO and President. We are pleased with the first commercial sale of this product...
|
|
|
Distinct Pharmacokinetic Profile and Safety of a Fixed-Dose Tablet of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine
Haberer LJ et al.The combination tablet of sumatriptan/naproxen sodium has unique pharmacokinetic properties. The rapid absorption of sumatriptan with the delayedrelease properties of naproxen sodium from sumatriptan/naproxen sodium might contribute...
|
|
|
Sumavel DosePro and Levadex to earn up to $400M by 2018
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which launched earlier this month in the United States,...
|
|
|
Sumavel DosePro and Levadex are Forecasted to Earn Approximately $400 Million in Combined Sales By 2018 in the
WALTHAM, Mass., Jan.26 /PRNewswire/ Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which launched...
|
|
|
Sumavel DosePro and Levadex are Forecasted to Earn Approximately $400 Million in Combined Sales By 2018 in the Migraine Drug Market
WALTHAM, Mass., Jan.26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which...
|
|
|
MUR master
Jennifer Richardson finds out how C+Ds 2009 MUR Champion of the Year made the service a success Justin Gilbody has turned MURs into a comprehensive health consultation, including blood pressure tests, weight management advice, BMI checks, stop smoking guidance,...
|
|
|
India's Dr Reddy's posts unexpected 3rd-qtr loss, revises forecasts
posts unexpected 3rd-qtr loss, revises forecasts - Pharmaceutical and News - Pharma Letter You are not logged in Keywords: Dr Reddy's, India, Financial results Related 2 November 200927 October 200928 October 200913 October 200919 January 2010 Recent 21 January...
|
|
|
Dr. Reddys posts Q3 loss
Reddy's Laboratories, one of India's top pharma compnaies by sales has reported a loss in its third quarter results as a result of losses at its German unit which it acquired a couple of years ago.Its consolidated revenues was Rs. 17.3 billion ($373...
|
|
|
Dr Reddy's posts Rs 522-crore net loss
Writes down intangible assets in German unit; pares years forecast.Dr Reddys Laboratories, the countrys second biggest drug maker, revealed an unexpected consolidated net loss of Rs 522 crore in the October-December quarter, due to a writedown of intangible...
|
|
|
First-of-its-kind migraine treatment available -- Zogenix's Sumavel DosePro
Innovative Needle-Free Delivery System Provides Fast Migraine Relief SAN DIEGO and DEERFIELD, Ill., Jan.13 /PRNewswire/ -- Zogenix, Inc. ('Zogenix'), a privately held pharmaceutical company, and Astellas Pharma U.S., Inc. ('Astellas') announced today the...
|
|
|
Dr. Reddy's Q3 FY10 Financial Results
Revenues at Rs.17,296 million EBITDA at Rs. 3,666 million Profits after Tax adjusted for impairment at Rs. 2,307 million HYDERABAD, India--(BUSINESS WIRE)--Jan 20, 2010 - Dr. Reddy's Laboratories Ltd. (NYSE:RDY) today announced its unaudited...
|
|
|
Dr. Reddys Q3 FY10 Financial Results
Reddys Laboratories Ltd.(NYSE:RDY) today announced its unaudited financial results for the third quarter ended December 31, 2009 under International Financial Reporting Standards (IFRS). Key Highlights *Note: Adjusted PAT represents PAT adjusted for one...
|
|
|
Dr. Reddys Laboratories reports financial results for third-quarter ended December 31, 2009
Gross profit at Rs.8.8 billion ($190 million) in Q3 FY10 represents a margin of 51% to revenues as against 56% in Q3 FY09. This change in gross margins is on account of a favorable mix of high margin revenues from sumatriptan in the previous year.
|
|
|
SUMAVEL„ DosePro„ Available in the United States to Treat Acute Migraine and Cluster Headaches
Let the jobs come to you!SAN DIEGO, Calif! and DEERFIELD, Ill., January 13, 2010 Zogenix, Inc.(Zogenix), a privately held pharmaceutical company, and Astellas Pharma US, Inc.(Astellas) announced today the U.S. commercial launch of SUMAVEL DosePro (...
|
|
|
Medical News: SUMAVEL(TM) DosePro(TM) Available In The United States To Treat Acute Migraine And Cluster Headaches
Zogenix, Inc.("Zogenix"), a privately held pharmaceutical company, and Astellas Pharma U.S., Inc. ("Astellas") announced the U.S. commercial launch of SUMAVEL DosePro (sumatriptan injection) needle-free delivery system. In July 2009, the U.S.
|
|
|
Zogenix and Astellas Pharma launches migraine drug in US
(Datamonitor via COMTEX) -- Zogenix and Astellas Pharma US, a subsidiary of Astellas Pharma, has announced the US commercial launch of Sumavel DosePro needle-free delivery system.In July 2009, the FDA approved Sumavel DosePro for the acute treatment of...
|
